J 2012

Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry

STUDNIČKA, Jan, Eva RENCOVÁ, Pavel ROZSÍVAL, Jaroslava DUŠOVÁ, Zora DUBSKÁ et. al.

Basic information

Original name

Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry

Authors

STUDNIČKA, Jan (203 Czech Republic), Eva RENCOVÁ (203 Czech Republic), Pavel ROZSÍVAL (203 Czech Republic), Jaroslava DUŠOVÁ (203 Czech Republic), Zora DUBSKÁ (203 Czech Republic), Oldřich CHRAPEK (203 Czech Republic), Petr KOLÁŘ (203 Czech Republic), Vít KANDRNAL (203 Czech Republic, belonging to the institution), Šárka PITROVÁ (203 Czech Republic) and Jiří ŘEHÁK (203 Czech Republic, guarantor)

Edition

Biomedical Papers, Olomouc, 2012, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 0.990

RIV identification code

RIV/00216224:14110/12:00062539

Organization unit

Faculty of Medicine

DOI

UT WoS

000312983100013

Keywords in English

age-related macular degeneration; choroidal neovascular membrane; visual acuity; ranibizumab; pegaptanib; photodynamic therapy with verteporfin
Změněno: 11/11/2019 12:43, Mgr. Tereza Miškechová

Abstract

V originále

Aims. To determine the effectiveness of second line treatments in patients with neovascular AMD who did not respond adequately to primary treatment. Methods. Retrospective, multicentre assessment. The frequency of primary treatment failure and outcomes of subsequent secondary treatment were assessed according to the type of primary treatment, type of CNV and change in BCVA over a 12 month period. Results. At the time of assessment 750 entries (750 treated eyes, 725 treated patients) had follow-up longer than 12 months. A treatment change required 7.7% subjects treated with ranibizumab, 20.5% with pegaptanib and 22% with PDT and verteporfin. Average BCVA of all patients at the beginning of primary treatment was 50.7 +/- 3 letters and 43 +/- 3.5 letters in 12th month (P<0.001). The mean decrease in BCVA was 7.7 +/- 0.6 letters during the first 6 months of observation. During the next 6 months, no significant change occurred. The change of primary therapy was required on average after 6.5 +/- 2.1 months. Conclusion. BCVA loss was the most significantly decelerated in patients who received ranibizumab as a secondary therapy following unsuccessful treatment with pegaptanib sodium.

Links

MUNI/A/0841/2011, interní kód MU
Name: Zlepšení kvality života optimalizace funkce zrakového orgánu (Acronym: ZKZOFZA)
Investor: Masaryk University, Category A